Fig. 2
From: Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression
FTO mediates m6A modification upregulation during ferroptosis and regulates ferroptosis. (A-B) CRC cells treated with 5 µM, 10 µM, and 20 µM of Erastin (or 200 nM, 400 nM, and 800 nM of RSL3) for 72 h. The lysates were collected for western blotting to examine the expression of FTO, ALKBH5, METTL3, METTL14, and YTHDF2. (C-D) CRC cells pr-treated with 20 µM of Erastin (or 800 nM of RSL3) for 4 h, subsequently treated with or without of DFO (DFO; 100 nM) for 72 h. The lysates were collected for western blotting to examine the expression of FTO, ALKBH5, METTL3, and METTL14. (E-F) FTO knockdown or vector control CRC cells treated with 20 µM of Erastin (or 800 nM of RSL3) for 72 h, and then the total RNA were harvested for ELISA to determine the m6A levels. (G-H) The malondialdehyde (MDA) concentration or GSH/GSSG ratio were detected using assay kits in FTO knockdown or vector control CRC cells. (I-J) The MDA concentration or GSH/GSSG ratio were detected using assay kits in FTO knockdown or vector control CRC cells treated with or without 100 nM DFO for 72 h. (K-L) The MDA concentration or GSH/GSSG ratio were detected using assay kits in FTO knockdown or vector control CRC cells treated with or without 100 nM Fer-1 for 72 h. (All error bars, mean values ± SEM, p values were determined by unpaired two-tailed Student’s t test of n = 3 independent biological experiments. *p < 0.05; **p < 0.01; ***p < 0.001)